SCHEMBL18655360

SCHEMBL18655360

CNc1c2ccccc2nc2c1ccc1cccnc12

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR1 P32246 4/20 0.47
CCR8 P51685 4/20 0.47
CCR5 P51681 3/20 0.47
LMNA P02545 3/20 0.47
CYP3A4 P08684 2/20 0.47
KDM4E B2RXH2 2/20 0.47
MAPT P10636 2/20 0.47
GMNN O75496 1/20 0.47
TP53 P04637 1/20 0.47
HSP90AA1 P07900 1/20 0.47
MMP2 P08253 1/20 0.47
CYP2D6 P10635 1/20 0.47
MMP9 P14780 1/20 0.47
ALOX15 P16050 1/20 0.47
TSHR P16473 1/20 0.47
NFKB1 P19838 1/20 0.47
MMP8 P22894 1/20 0.47
THPO P40225 1/20 0.47
MTOR P42345 1/20 0.47
HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18655364 0.83 ADORA2A (0.44) CCR1CCR8CCR5LMNACYP3A4
SCHEMBL18655365 0.83 MAOA (0.50) LMNAKDM4EMAPTL3MBTL1KDM1A
SCHEMBL18655363 0.82 CCR1 (0.41) CCR1CCR8CCR5LMNACYP3A4
SCHEMBL20208247 0.78 CCR1 (0.53) CCR1CCR8CCR5LMNACYP3A4
SCHEMBL18650755 0.77 KDM4E (0.53) CCR1CCR8CCR5LMNACYP3A4
SCHEMBL20208231 0.77 MAOA (0.53) CCR1CCR8CCR5LMNACYP3A4
SCHEMBL20208358 0.77 CCR1 (0.52) CCR1CCR8CCR5LMNACYP3A4
SCHEMBL20208357 0.76 CCR1 (0.50) CCR1CCR8CCR5LMNACYP3A4
SCHEMBL21308996 0.76 CCR1 (0.50) CCR1CCR8CCR5LMNACYP3A4
SCHEMBL5410460 0.75 KDM1A (0.66) LMNAKDM4EMAPTSMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170081351-A1 Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith WAKE FOREST UNIVERSITY 2017-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081351-A1 Design, Synthesis, and Biological Activity of Platinum-benz[c]acridine Hybrid Agents and Methods Associated Therewith ACR, TP53, MCL1 CCR1 292/4885CCR8 499/4885CCR5 645/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.